

Oncologists' experiences with drug shortages

Kenneth L. Kehl, MD (KLK); Stacy W. Gray, MD (SWG); Benjamin Kim, MD (BK); Katherine L. Kahn, MD (KK); David Haggstrom, MD, MAS (DH); Maryse Roudier, MPH (MR); Nancy L. Keating, MD, MPH (NLK)

From the MD Anderson Cancer Center, Houston, TX (KLK); Dana-Farber Cancer Institute, Boston, MA (SWG); University of California, San Francisco, CA (BK); University of California, Los Angeles and RAND Corporation, Santa Monica, CA (KK); Indiana University School of Medicine and the Indianapolis VA (DH); Frontier Science and Research Corporation, Boston, MA (MR); and the Department of Health Care Policy, Harvard Medical School, and Brigham and Women's Hospital, Boston, MA (NLK).

Address correspondence to Nancy L. Keating, MD, MPH, Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, Phone: 617-432-3093, Fax: 617-432-0173, E-mail: keating@hcp.med.harvard.edu

Appendix 2 Survey items to ascertain experiences with drug shortages.

1. Drug manufacturers have alerted the FDA about shortages of a number of generic injectable drugs. In the past 12 months, how, if at all, have shortages of the following drugs affected your ability to treat **your patients with lung or colorectal cancer**? If you have needed to use alternative treatments, please indicate the number of patients affected.

(MARK **ONE BOX** IN EACH ROW; IF YOU USED OTHER TREATMENTS, INCLUDE THE NUMBER OF PATIENTS AFFECTED)

	I have needed to use an equally-effective alternative	I have needed to use a less-effective alternative	I have not been affected by the shortage	I do not use this drug
a. Cisplatin	1 <input type="checkbox"/> ___ patients	2 <input type="checkbox"/> ___ patients	3 <input type="checkbox"/>	4 <input type="checkbox"/>
b. Etoposide	1 <input type="checkbox"/> ___ patients	2 <input type="checkbox"/> ___ patients	3 <input type="checkbox"/>	4 <input type="checkbox"/>
c. Fluorouracil	1 <input type="checkbox"/> ___ patients	2 <input type="checkbox"/> ___ patients	3 <input type="checkbox"/>	4 <input type="checkbox"/>
d. Leucovorin	1 <input type="checkbox"/> ___ patients	2 <input type="checkbox"/> ___ patients	3 <input type="checkbox"/>	4 <input type="checkbox"/>
e. Paclitaxel	1 <input type="checkbox"/> ___ patients	2 <input type="checkbox"/> ___ patients	3 <input type="checkbox"/>	4 <input type="checkbox"/>
f. Cyanocobalamin (B12) injection	1 <input type="checkbox"/> ___ patients	2 <input type="checkbox"/> ___ patients	3 <input type="checkbox"/>	4 <input type="checkbox"/>
g. Dexamethasone injection	1 <input type="checkbox"/> ___ patients	2 <input type="checkbox"/> ___ patients	3 <input type="checkbox"/>	4 <input type="checkbox"/>

2. If you have had experience with changes in treatment or delays due to drug shortages, please describe in more detail here _____
